

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21-261

CHEMISTRY REVIEW(S)

**DIVISION OF SPECIAL PATHOGENS AND IMMUNOLOGIC DRUG
PRODUCTS**

Review of Chemistry, Manufacturing, and Controls

NDA #: 21-261

CHEM.REVIEW #: 1

REVIEW DATE: 9/12/00

SUBMISSION/TYPE

DOCUMENT DATE

CDER DATE

ORIGINAL

3/31/00

4/3/00

Amendment (BZ)

9/7/00

9/8/00

NAME & ADDRESS OF APPLICANT:

Personal Products Company
199 Grandview Road
Skillman, New Jersey 08558
Ph# (908) 904-3745

CONTACT:

Lynn A. Pawelski, Director, Regulatory Affairs

DRUG PRODUCT NAME:

Proprietary: Monistat 3 Cream Combination Pack

Established: miconazole nitrate vaginal cream

Code #: n/a

PHARMACOLOGICAL CATEGORY/INDICATION:

Treatment of vulvovaginal candidiasis.

DOSAGE FORM: Vaginal Cream

STRENGTHS: 4% cream (200 mg per applicator) intravaginally
2% cream externally

ROUTE OF ADMINISTRATION: Intravaginal and external vulvar


Rx/OTC: OTC

**CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA,
MOLECULAR WEIGHT:**

Miconazole nitrate, $C_{18}H_{14}Cl_4N_2O \cdot HNO_3$, MW = 479.15

(1) 1*H*-Imidazole, 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-, mononitrate

(2) 1-[2,4-Dichloro- β -[(2,4-dichlorobenzyl)oxy]phenethyl]imidazole mononitrate
CAS 22832-87-7



SUPPORTING DOCUMENTS:

NDA 17-450 and NDA 20-827

RELATED DOCUMENTS: n/a

CONSULTS:

Environmental Assessment (categorical exclusion request acceptable).

REMARKS/COMMENTS:

Monistat 3 Cream Combination Pack is a new product for the treatment vaginal fungal infections and consists of two miconazole nitrate vaginal creams. It is proposed as a co-package of Monistat 3 Vaginal Cream (three prefilled applicators containing 4% miconazole nitrate cream, 200 mg miconazole nitrate per applicator) and Monistat 7 Vaginal Cream (9 g tube containing 2% miconazole nitrate cream) to be used intra- and extravaginally, respectively. Both creams in their proposed container/closure systems are marketed and approved drug products via NDA 20-827 (Monistat 3 Vaginal Cream) and 17-450 (Monistat 7 Vaginal Cream), respectively. These NDAs will serve as sources of the CMC information for the current cream combination product and will be referenced for CMC details regarding the drug substance (miconazole nitrate) and both drug products (miconazole nitrate vaginal creams, 4% and 2%). Therefore, no additional CMC

review of the current NDA is necessary. The labeling and the trademark issues have been discussed with the applicant and are included in the labeling review (for details refer to the labeling review of this NDA conducted by the OTC Division).

CONCLUSIONS & RECOMMENDATIONS:

From the chemistry, manufacturing and controls viewpoint, the NDA is recommended for approval provided that the applicant will adequately address all the labeling issues.

/S/

Dorota Matecka, Ph.D.
Review Chemist, HFD-590

/S/

Norman R. Schmuff, Ph.D.
Team Leader, HFD-590

cc: Org. NDA 21-261
HFD-590/Division File
HFD-590/Team Leader/NSchmuff
HFD-830/DivDir/CChen
HFD-560/PM/DKeravich
HFD-590/PM/CChi
HFD-590/Chem/DMatecka
District Office